Klinisch Onderzoek
Follow
Find
19 views | +0 today
Rescooped by NCTC from Pharmaceutics_R&D
onto Klinisch Onderzoek
Scoop.it!

US pharma: 465 drugs in R&D for chronic diseases affecting over-65s

US pharma: 465 drugs in R&D for chronic diseases affecting over-65s | Klinisch Onderzoek | Scoop.it

US biopharmaceutical companies are currently developing 465 new medicines that target the 10 leading chronic conditions affecting people aged 65 and over, according to new industry data.

The medicines, which are all now in clinical trials or under review by the Food and Drug Administration (FDA), are diverse in scope, notes the Pharmaceutical Research and Manufacturers of America (PhRMA), which has published the data. (...) - by Lynne Taylor, PharmaTimes, March 22, 2013


Via Julien Hering, PhD
NCTC's insight:

Interesting, also in light of the Dutch IEMO project which aims at including seniors in clinical trials to measure the effect durgs have have on them.

more...
No comment yet.
Your new post is loading...
Your new post is loading...
Scooped by NCTC
Scoop.it!

Re-thinking Clinical Trials for the World of Crowdsourcing - Xconomy

Re-thinking Clinical Trials for the World of Crowdsourcing - Xconomy | Klinisch Onderzoek | Scoop.it
Disruption isn’t a word normally associated with clinical drug development, but nevertheless it is coming. We can feel the rumblings of it. New technologie
more...
No comment yet.
Scooped by NCTC
Scoop.it!

Sanofi partners with PatientsLikeMe to promote its clinical trials - PMLiVE

Sanofi partners with PatientsLikeMe to promote its clinical trials - PMLiVE | Klinisch Onderzoek | Scoop.it
more...
No comment yet.
Scooped by NCTC
Scoop.it!

Startup biotech charges into PhII with $23M bankroll for rare disease drugs

Startup biotech charges into PhII with $23M bankroll for rare disease drugs | Klinisch Onderzoek | Scoop.it
A little more than a year ago the startup crew at Lumena Pharmaceuticals was based in North Carolina and working on a new drug for diabetics. But things have changed.
more...
No comment yet.
Scooped by NCTC
Scoop.it!

Article > India tightens up clinical-trial monitoring

Article > India tightens up clinical-trial monitoring | Klinisch Onderzoek | Scoop.it
more...
No comment yet.
Scooped by NCTC
Scoop.it!

Covance bets on Singapore with central lab expansion

Covance bets on Singapore with central lab expansion | Klinisch Onderzoek | Scoop.it
more...
No comment yet.
Scooped by NCTC
Scoop.it!

At long last, Sony and Olympus launch medical device joint venture

At long last, Sony and Olympus launch medical device joint venture | Klinisch Onderzoek | Scoop.it
more...
No comment yet.
Scooped by NCTC
Scoop.it!

Want China? Get ready to wheel-and-deal on drug prices

Want China? Get ready to wheel-and-deal on drug prices | Klinisch Onderzoek | Scoop.it
more...
No comment yet.
Scooped by NCTC
Scoop.it!

Article > AllTrials campaign announces next steps

Article > AllTrials campaign announces next steps | Klinisch Onderzoek | Scoop.it
more...
No comment yet.
Scooped by NCTC
Scoop.it!

Article > New UK tax breaks benefit life sciences groups from this week

Article > New UK tax breaks benefit life sciences groups from this week | Klinisch Onderzoek | Scoop.it
more...
No comment yet.
Scooped by NCTC
Scoop.it!

Article > Enrolment swells Phase III oncology costs

Article > Enrolment swells Phase III oncology costs | Klinisch Onderzoek | Scoop.it
more...
No comment yet.
Scooped by NCTC
Scoop.it!

Merck sues India's Glenmark for stomping on Januvia patent

Merck sues India's Glenmark for stomping on Januvia patent | Klinisch Onderzoek | Scoop.it
more...
No comment yet.
Scooped by NCTC
Scoop.it!

GSK, Astra among shoppers for $1B Optimer deal: Bloomberg

GSK, Astra among shoppers for $1B Optimer deal: Bloomberg | Klinisch Onderzoek | Scoop.it
more...
No comment yet.
Rescooped by NCTC from Pharmaceutics_R&D
Scoop.it!

US pharma: 465 drugs in R&D for chronic diseases affecting over-65s

US pharma: 465 drugs in R&D for chronic diseases affecting over-65s | Klinisch Onderzoek | Scoop.it

US biopharmaceutical companies are currently developing 465 new medicines that target the 10 leading chronic conditions affecting people aged 65 and over, according to new industry data.

The medicines, which are all now in clinical trials or under review by the Food and Drug Administration (FDA), are diverse in scope, notes the Pharmaceutical Research and Manufacturers of America (PhRMA), which has published the data. (...) - by Lynne Taylor, PharmaTimes, March 22, 2013


Via Julien Hering, PhD
NCTC's insight:

Interesting, also in light of the Dutch IEMO project which aims at including seniors in clinical trials to measure the effect durgs have have on them.

more...
No comment yet.
Scooped by NCTC
Scoop.it!

Article > Pfizer drug fails in Phase III NHL trial

Article > Pfizer drug fails in Phase III NHL trial | Klinisch Onderzoek | Scoop.it
more...
No comment yet.
Scooped by NCTC
Scoop.it!

Article > Health Research Authority sets out stall on trial transparency

Article > Health Research Authority sets out stall on trial transparency | Klinisch Onderzoek | Scoop.it
more...
No comment yet.
Scooped by NCTC
Scoop.it!

Aantal medicijnonderzoeken daalt - Nieuws - Mednet

Aantal medicijnonderzoeken daalt - Nieuws - Mednet | Klinisch Onderzoek | Scoop.it
Het aantal klinische onderzoeken naar medicijnen in Europa daalt de afgelopen jaren behoorlijk. Maar in Oost-Europa, en vooral in Polen, vinden juist steeds meer klinische onderzoeken plaats.
more...
No comment yet.
Scooped by NCTC
Scoop.it!

Proteus Digital Health raises $45 million, inks clinical trials deal with Oracle | mobihealthnews

Proteus Digital Health raises $45 million, inks clinical trials deal with Oracle | mobihealthnews | Klinisch Onderzoek | Scoop.it
NCTC's insight:

Interesting new way to give more insight while conducting Clinical Trials, very promosing prospects for further research as well once enough data has been gathered.

more...
No comment yet.
Scooped by NCTC
Scoop.it!

Article > Acorda pursues stroke indication for MS drug Ampyra

Article > Acorda pursues stroke indication for MS drug Ampyra | Klinisch Onderzoek | Scoop.it
more...
No comment yet.
Scooped by NCTC
Scoop.it!

EU, North America fall behind as clinical trial locations for EMA-submitted medicines - PMLiVE

EU, North America fall behind as clinical trial locations for EMA-submitted medicines - PMLiVE | Klinisch Onderzoek | Scoop.it
more...
No comment yet.
Scooped by NCTC
Scoop.it!

Article > Experts urge Australia to act on pharma IP, clinical trials

Article > Experts urge Australia to act on pharma IP, clinical trials | Klinisch Onderzoek | Scoop.it
more...
No comment yet.
Scooped by NCTC
Scoop.it!

Article > Astellas signs $300 million cancer pact with Ambrx

Article > Astellas signs $300 million cancer pact with Ambrx | Klinisch Onderzoek | Scoop.it
more...
No comment yet.
Rescooped by NCTC from New pharma
Scoop.it!

Digital technologies & analytics as top strategic priority in 2013 for pharma

Digital technologies & analytics as top strategic priority in 2013 for pharma | Klinisch Onderzoek | Scoop.it
Maybe the gap between consumer packaged good marketers and pharma marketers is finally closing. According to a new Accenture Report  ”the sales and marketing models of today need to be reshaped in order to be successful in today’s “new normal.  Reducing costs, mastering multichannel marketing and improving digital effectiveness are the top strategic priorities for pharmaceutical sales and marketing executives.”

Accenture says, There is a customer engagement revolution in motion in the Life Sciences industry as it faces life in the “new normal” after the peak of the patent cliff1. The industry is in an era where targeting specific populations and improving patient outcomes is critical for specialty products and where reaching more customers in rapidly developing markets is paramount for growth. This revolution is requiring companies to rethink how they can reach patients, payers, providers and governments in both mature and emerging markets—at speed, at the right price and with the right information for each target audience. This is a significant change from the “feet on the street,” single message selling model that worked well for blockbuster drugs in mature healthcare markets.

And I think I finally found out why agency people are reporting that pharma is spending more in digital marketing. According to the report

The use of third-party service providers is a relatively common practice in the industry that will continue to increase.

...

The real challenge is can third parties really provide the best analytics and digital marketing strategy as someone who actually works within the brand team/company?  It has been my experience that too many pharma companies treat third parties as vendors and don’t always share every bit of important information. Even more important outside agencies need to understand the dynamics, including the corporate politics, within the organization.  Employees who don’t understand digital marketing and want to hold onto more “glamorous” channels like TV may fight the shift in dollars to analytics and digital marketing. Still this is great news for pharma which has a reputation of coming late to the party.


Via rob halkes
more...
rob halkes's curator insight, April 4, 2013 10:17 AM

Watch the experience of the blogger by this observation: "It has been my experience that too many pharma companies treat third parties as vendors and don’t always share every bit of important information.".. It resembles my own experience. Hence, indeed, using social channels for one's marketing intetnions is not easy to do: the whole company and its strategy is at stake. Not an easy thing so and one needs to make precautions!

By the way, look here for the reference to the very Accenture survey:

http://bit.ly/Y0jjWC

 

Scooped by NCTC
Scoop.it!

Article > GSK's four strain flu jab wins approval in UK, Germany

Article > GSK's four strain flu jab wins approval in UK, Germany | Klinisch Onderzoek | Scoop.it
more...
No comment yet.
Scooped by NCTC
Scoop.it!

Resurgent Pfizer partners with Bind on new nanotech drug effort

Resurgent Pfizer partners with Bind on new nanotech drug effort | Klinisch Onderzoek | Scoop.it
more...
No comment yet.
Rescooped by NCTC from Pharmaceutics_R&D
Scoop.it!

Drug-company data vaults to be opened

Drug-company data vaults to be opened | Klinisch Onderzoek | Scoop.it

European agency will publish firms’ clinical-trial results.


International calls for the pharmaceutical industry to share the results of clinical trials have grown ever more intense amid revelations that high-profile companies have hidden crucial data on safety and efficacy. Now Europe is moving towards measures that would significantly increase disclosure of such data. (...) - by Daniel Cressey, Nature, 27 March 2013


Via Julien Hering, PhD
more...
No comment yet.